1
Avinash G Thombre: Dispensing device containing a hydrophobic medium. Pfizer, Peter C Richardson, Gregg C Benson, A Dean Olson, July 11, 1995: US05431921 (347 worldwide citation)

A device for the controlled delivery of an insoluble or partially aqueous insoluble beneficial agent to an aqueous containing environment. The device comprises a shaped wall that surrounds and defines an internal reservoir. The wall is formed at least in part of a sintered polymer microporous membra ...


2
Robert L Dow, Kevin Koch, Gary R Schulte: 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors. Pfizer, Peter C Richardson, Gregg C Benson, A Dean Olson, January 14, 1997: US05593997 (138 worldwide citation)

Certain 4-aminopyrazolo[3,4-d]pyrimidine compounds, and their pharmaceutically-acceptable salts and prodrugs, are inhibitors of tyrosine kinase enzymes and are useful for immunoregulation and for the treatment of cancer, angiogenesis and atherosclerosis.


3
John R Cardinal, Scott M Herbig, Richard W Korsmeyer, Jeelin Lo, Kelly L Smith, Avinash G Thombre: Asymmetric membranes in delivery devices. Pfizer, Peter C Richardson, Gregg C Benson, A Dean Olson, December 16, 1997: US05698220 (70 worldwide citation)

A device for controlled release of an active substance through one or more asymmetric membranes by diffusion and/or osmotic pumping.


4
Bruce F Kay: Honeycomb spliced multilayer foam core aircraft composite parts and method for making same. United Technologies Corporation, A Dean Olson, August 18, 1987: US04687691 (59 worldwide citation)

Aircraft composite components having foam cores comprising at least two foam sheets joined with a sheet of honeycomb to form a foam-honeycomb-foam sandwich. The layers of sheet foam are in contact with each other and the honeycomb cells extend a substantially equal depth into and generally perpendic ...


5
Michael P DeNinno, George T Magnus Aryitey, Roger B Ruggeri, Ronald T Wester: 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines. Pfizer, Peter C Richardson, Gregg C Benson, A Dean Olson, October 31, 2000: US06140343 (56 worldwide citation)

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and trig ...


6
John R Cardinal, Scott M Herbig, Richard W Korsmeyer, Jeelin Lo, Kelly L Smith, Avinash G Thombre: Use of asymmetric membranes in delivery devices. Pfizer, Peter C Richardson, Gregg C Benson, A Dean Olson, March 18, 1997: US05612059 (54 worldwide citation)

A device for controlled release of an active substance through one or more asymmetric membranes by diffusion and/or osmotic pumping.


7
Bruce A Hay: Methods for making tetrahydroisoalpha and hexahydroisoalpha acids. Pfizer, Peter C Richardson, J Trevor Lumb, A Dean Olson, May 7, 1991: US05013571 (54 worldwide citation)

A method of converting alpha acids to hop flavors by exposing the alpha acids to an environment capable of substantially simultaneously isomerizing and reducing the alpha acids to form either THIAA or HHIAA. Another aspect of this invention is directed to a method of reducing hop flavors by exposing ...


8
Michael P DeNinno, Christian J Mularski, Roger B Ruggeri, Ronald T Wester: 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines. Pfizer, Peter C Richardson, Gregg C Benson, A Dean Olson, November 14, 2000: US06147090 (51 worldwide citation)

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and trig ...


9
William J Curatolo: Dispensing device powered by hydrogel. Pfizer, Peter C Richardson, Gregg C Benson, A Dean Olson, May 14, 1996: US05516527 (49 worldwide citation)

This invention relates to devices useful for the controlled delivery of one or more beneficial agents to an environment of use. More specifically, this invention concerns such devices which are powered by hydrogel. This invention also relates to the controlled delivery of one or more beneficial agen ...


10
Ernest S Hamanaka: N-aryl and N-heteroarylurea derivatives as inhibitors of acyl coenzyme A: Cholesterol acyl transferase (ACAT). Pfizer, Peter C Richardson, Gregg C Benson, A Dean Olson, December 14, 1999: US06001860 (46 worldwide citation)

A compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.17, R.sup.18 and R.sup.1 are as defined below. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis ...